UCB drugs company invests $20m and signs licensing agreement worth up to $725m with Synosia Therapeutics.
Belgium-based drugs company UCB has invested $20m in Swiss peer Synosia Therapeutics’ series C round in return for exclusive, worldwide rights to the development of two compounds for Parkinson’s disease.
As part of the license, Synosia will also receive an undisclosed upfront payment and could receive potential regulatory and commercial milestone payments of up to $725m across both compounds.
Ismail Kola, executive vice president of drug discovery and president of UCB New Medicines, said: "With access to these two potentially…
